ImmunityBio Target of Unusually Large Options Trading (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) was the target of unusually large options trading on Friday. Investors acquired 9,749 call options on the company. This represents an increase of 125% compared to the typical daily volume of 4,330 call options.

Analyst Upgrades and Downgrades

IBRX has been the subject of a number of analyst reports. Piper Sandler reduced their price objective on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday.

Institutional Investors Weigh In On ImmunityBio

Several institutional investors have recently bought and sold shares of IBRX. Victory Capital Management Inc. raised its position in shares of ImmunityBio by 16.0% during the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock worth $126,000 after buying an additional 2,746 shares in the last quarter. Wealth Effects LLC increased its stake in shares of ImmunityBio by 3.4% during the third quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock valued at $337,000 after acquiring an additional 3,000 shares during the period. Exchange Traded Concepts LLC raised its holdings in ImmunityBio by 8.4% during the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock worth $178,000 after purchasing an additional 3,722 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in ImmunityBio by 3.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 123,879 shares of the company’s stock worth $667,000 after purchasing an additional 4,533 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Trading Up 26.4 %

Shares of NASDAQ:IBRX opened at $5.32 on Friday. The firm’s 50 day moving average is $3.72 and its two-hundred day moving average is $5.34. The firm has a market capitalization of $3.68 billion, a P/E ratio of -4.88 and a beta of 1.02. ImmunityBio has a 52 week low of $1.62 and a 52 week high of $10.53.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, August 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.53 million. Analysts predict that ImmunityBio will post -0.86 EPS for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.